Breaking News
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Innovative strategy opens up new avenue of treatment for anthrax infections
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Drug cocktail that increases lifespan discovered
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
Study findings could lead to less expensive and more effective cancer treatments

Study findings could lead to less expensive and more effective cancer treatments

image_pdfDownload PDFimage_print

The latest generation of cancer treatments spring from the discovery that the human immune system is able to beat the disease. Like Dorothy in “The Wizard of Oz,” what research teams around the world have spent decades searching for was right in their own backyard all along.

Adoptive cell transfer, or ACT, is one of these new immune-based treatments. For ACT, doctors draw a sample of blood from a cancer patient, sift out naturally occurring immune system T cells and re-engineer them in a laboratory, turning them into super-charged, cancer fighters. Then, billions of these killer T cells are put back into the patient’s bloodstream, where they hunt down and destroy the cancer.

ACT is now one of the most effective treatments for melanoma and many blood-based cancers. Unfortunately, it is not very effective against aggressive solid tumors, such as pancreatic cancer. The problem is there are hundreds of types of T cells in the body, and not all of them make good cancer fighters. It is very difficult to identify and sift out the exact T cells needed to fight highly malignant tumors. The T cells must be able to both navigate their way to the tumor and survive long enough in the harsh cancer environment to kill all of the cancer.

Luckily, identifying these resilient, cancer-killing T cells just got a lot easier, thanks to a team of Hollings Cancer Center researchers at the Medical University of South Carolina (MUSC), led by Chrystal Paulos, Ph.D., associate professor of Microbiology and Immunology and the Cecilia and Vincent Peng Endowed Chair in Melanoma and Cutaneous Oncology. Their breakthrough discovery, published in the December 2017 issue of Nature Communications, finds that T cells with a protein called CD26 on their surface have the best cancer-fighting potential.

The road to this discovery began when the team started looking at a group of T cells that are not widely used for ACT. There are many different T cell ‘families,’ and most ACT treatments use T cells from the CD8 family. But the Paulos team chose to focus on the CD4 family.

Stefanie Bailey, a graduate student on Paulos’ team and lead author on the article, explains. “CD4 T cells get overlooked in cancer immunotherapy. There’s a bias in the field to study CD8 T cells, because they’re known to have strong anti-cancer abilities,” she says. “CD4 T cells are mostly known for helping other cells function — in fact, CD4 T cells are called ‘T-helper cells.’ But studies show that CD4 T cells can also clear cancer.”

Last spring, the team discovered that a particular type of CD4 T cells, called Th17 cells, were highly effective against aggressive solid tumors. But they needed a way to identify Th17 cells in a blood sample, so they could sift them out and use them for ACT therapy. Then, a new study caught Bailey’s attention. It showed that T cells with a protein called CD26 on their surface carried markers for Th17.

“We were looking for a way to get Th17 cells directly from patients’ blood to get around having to generate them in the lab, which is a very complex process,” says Bailey. “We needed a simple way to identify Th17 cells. So, when we saw that Th17 cells express high levels of CD26, we wanted to explore it. CD26 is a multi-functional protein that’s on the surface of the cell. It’s actually pretty well-known in the immunology field.”

Although CD26 was well known, Paulos’ team was the first to study its role in fighting cancer. The first thing they found was that all CD4 T cells did not have the same amount of CD26 on the surface. Some had little or no CD26, some had intermediate levels and others had high CD26. In addition, these three T cell groups had very different abilities to fight cancer.

The team expected T cells with high CD26 levels to perform worst against cancer, because initial tests showed that high-CD26 T cells had many hallmarks of being weak immune cells. To their surprise, closer study showed quite the opposite.

“We were really shocked to see that these cells could not only kill multiple solid tumors but also could survive for a long time in the patient,” says Bailey. “When you look at high-CD26 T cells, they look exhausted. They appear incapable of mounting a long-term response to cancer. They don’t look at all like the kind of T cells we would want for therapy,” she explains.

Despite their appearance, high-CD26 T cells had two critical characteristics the other two types lacked. First, they could resist apoptosis (processes that lead to cell death) and survive in the hostile tumor environment. Second, they had stem cell-like properties, allowing them to repopulate and keep growing after being infused into the patient.

“One of the beauties of ACT is that it’s a living therapy,” says Bailey. “After the T cells kill the tumor, they keep living inside the patient. So, if the tumor comes back, you already have T cells there that can kill it again.” Theoretically, ACT-infused T cells can last a lifetime. Viable, re-infused T cells have been found over twenty years later in ACT patients.

The team’s discovery that T cells with high levels of CD26 are excellent cancer fighters will help advance the use of T cell-based immunotherapies for cancer and other autoimmune diseases. Until now, researchers looked for multiple markers to identify the best T cells for ACT. This breakthrough suggests that the long list of markers can be shortened to just one: CD26.

“There are two really exciting things here,” says Bailey. “First, you can identify T cells with superior therapeutic potential by how much CD26 they have. So, you can maximize the chance that ACT will succeed in killing the cancer. Second, in the solid tumors we looked at, having T cells with CD26 at the tumor site produced a better therapeutic response, suggesting that having CD26 expression on tumor-infiltrating T cells directly correlates with the patient’s response.”

The study specifically looked at melanoma, mesothelioma and pancreatic cancer. Animal models bearing these types of tumors experienced a better treatment outcome when a heightened percentage of CD26 donor T cells infiltrated the tumor. There was a 50 percent curative rate in melanoma and 95 percent for mesothelioma. There was not a curative response for pancreatic cancer, but it did reduce tumor size by two-thirds and extend survival in the preclinical model. These findings suggest that it may work well in combination therapies, she says.

“We’re excited about the broader clinical implications of this discovery,” adds Paulos. “Targeting T cells with CD26 will not only benefit ACT therapy but will also help bolster the effectiveness of other cancer immunotherapies, such as checkpoint modulators, vaccines and cytokine therapies.” Paulos explained that human CD4 T cells expressing various amounts of CD26 could also be manipulated in treating patients with infectious diseases and autoimmune manifestations.

Now the Paulos laboratory is collaborating with investigators at MUSC and around the world to further explore the role of CD4 T cells with different CD26 levels in different types of cancer and autoimmune diseases. Beyond providing more effective treatments, it also offers other benefits. “If you get the right types of cells, maybe you don’t need as many. It could cut down on a lot of expenses and the time patients would need to get the treatment” says Paulos.​​

Source:

http://academicdepartments.musc.edu/newscenter/2017/Overlooked-immune-cells-show-promise-in-new-ACT-therapy/index.html

Tagged with:

About author

Related Articles